<DOC>
	<DOC>NCT00432627</DOC>
	<brief_summary>This study is to assess the pharmacokinetics of deferasirox in hepatically impaired patients compared to healthy volunteers.</brief_summary>
	<brief_title>Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Inclusion criteria for those with hepatic impairment: Physical signs consistent with a clinical diagnosis of liver cirrhosis ChildPugh Clinical Assessment Score consistent with degree of hepatic impairment Otherwise considered healthy Inclusion criteria for healthy volunteers: â€¢ In good health. Exclusion criteria for those with hepatic impairment: Clinically significant abnormal findings other than hepatic impairment Clinical evidence of severe ascites History of surgical portosystemic shunt Any evidence of progressive liver disease within the last 4 weeks Exclusion criteria for healthy controls: Clinical evidence of liver disease or liver injury A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result Use of any prescription medication within 1 month prior to dosing Other protocol defined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>adults</keyword>
	<keyword>deferasirox</keyword>
</DOC>